Malignant peritoneal mesothelioma

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Section editor
Nkv.jpg
Neeta K. Venepalli, MD, MBA, FACP
University of North Carolina
Chapel Hill, NC
1 regimens on this page
1 variants on this page


Guidelines

EURACAN/PSOGI

NCCN

Advanced or metastatic disease, subsequent lines of therapy

Atezolizumab & Bevacizumab

back to top

Regimen

Study Years of enrollment Evidence
Raghav et al. 2021 (MDACC 2016-0861) 2017-2019 Phase 2

Immunotherapy

Targeted therapy

21-day cycles

References

  1. MDACC 2016-0861: Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 Nov;11(11):2738-2747. Epub 2021 Jul 14. link to original article link to PMC article contains verified protocol PubMed NCT03074513